Publication
Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerHER2-Positive Breast Carcinomacivic_curation1.00
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugTrastuzumabcivic_curation1.00
- geneFCGR2Acivic_curation1.00
- geneFCGR2Bcivic_curation1.00
- geneFCGR3Acivic_curation1.00
- variantFCGR2A H167Rcivic_curation1.00
- variantFCGR2B I232Tcivic_curation1.00
- variantFCGR3A F212Vcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24989892
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FCGR2A H167R1 | ||||||||
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Does Not Support Sensitivity Response | 4 | accepted | EID10881325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between tr… (full text at CIViC) PMID 24989892 · Norton et al., 2014 · Open in CIViC | civic |
| FCGR3A F212V1 | ||||||||
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | B | Does Not Support Sensitivity Response | 4 | accepted | EID10871325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistically significant difference in disease-free survi… (full text at CIViC) PMID 24989892 · Norton et al., 2014 · Open in CIViC | civic |
| FCGR2B I232T1 | ||||||||
| (prognostic) | Malignant Breast Neoplasm | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID10861325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was a difference in disease-free survival for FCGR2B I232T, with … (full text at CIViC) PMID 24989892 · Norton et al., 2014 · Open in CIViC | civic |